Misplaced Pages

Olanzapine/fluoxetine

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from Symbyax) Antidepressant medication Pharmaceutical compound
Olanzapine/fluoxetine
Combination of
OlanzapineAtypical antipsychotic
FluoxetineSelective serotonin reuptake inhibitor
Clinical data
Trade namesSymbyax, Cinol Forte, Olapin Forte, others
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
  • AU: C
Routes of
administration
By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG
  (what is this?)  (verify)

Olanzapine/fluoxetine (trade name Symbyax, created by Eli Lilly and Company) is a fixed-dose combination medication containing olanzapine (Zyprexa), an atypical antipsychotic, and fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). Olanzapine/fluoxetine is primarily used to treat the depressive episodes of bipolar I disorder as well as treatment-resistant depression.

Medical uses

Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression.

Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).

Side effects

Possible side effects of olanzapine/fluoxetine include all those of the two component drugs: olanzapine (side effects) and fluoxetine (side effects). Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision, and difficulty concentrating.

Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine.

Olanzapine is correlated with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring.

In rare cases, olanzapine/fluoxetine may cause neuroleptic malignant syndrome.

Like other SSRIs, olanzapine/fluoxetine carries a boxed warning stating that it could increase the risk of suicidal thoughts and behaviors in patients aged 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.

See also

References

  1. ^ "Symbyax- olanzapine and fluoxetine hydrochloride capsule". DailyMed. 21 April 2020. Retrieved 30 September 2020.
  2. "Tratamento medicamentoso dos transtornos bipolares - Transtornos psiquiátricos". Manuais MSD edição para profissionais (in Brazilian Portuguese). Retrieved 2022-10-02.
  3. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M (October 2009). "Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis". The Journal of Clinical Psychiatry. 70 (10): 1424–1431. doi:10.4088/JCP.08m04772gre. PMID 19906346.
  4. Grohol, J. "FDA Approves Symbyax for Treatment Resistant Depression". Psych Central Blog. Archived from the original on 2017-12-26. Retrieved 2010-07-17.
  5. McIntyre R, Katzman M (2003). "The role of atypical antipsychotics in bipolar depression and anxiety disorders". Bipolar Disorders. 5 (Suppl 2): 20–35. doi:10.1111/j.1399-2406.2003.00061.x. PMID 14700010.
  6. Pederson KJ, Roerig JL, Mitchell JE (October 2003). "Towards the pharmacotherapy of eating disorders". Expert Opinion on Pharmacotherapy. 4 (10): 1659–1678. doi:10.1517/14656566.4.10.1659. PMID 14521477. S2CID 38506292.
  7. Koran LM, Ringold AL, Elliott MA (July 2000). "Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder". The Journal of Clinical Psychiatry. 61 (7): 514–517. doi:10.4088/JCP.v61n0709. PMID 10937610.
  8. Stein MB, Kline NA, Matloff JL (October 2002). "Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study". The American Journal of Psychiatry. 159 (10): 1777–1779. doi:10.1176/appi.ajp.159.10.1777. PMID 12359687.
  9. ^ "Symbyax". Drugs.com.

External links

Mood stabilizers
Anticonvulsants
Atypical antipsychotics
Others
Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
Tricyclic and tetracyclic antidepressants
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Monoamine oxidase inhibitors
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Adjunctive therapies
Miscellaneous
Anxiolytics (N05B)
5-HT1ARTooltip 5-HT1A receptor agonists
GABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulators
Hypnotics
Gabapentinoids
(α2δ VDCC blockers)
Antidepressants
Antipsychotics
Sympatholytics
(Antiadrenergics)
Others
Pharmacodynamics
Adrenergic receptor modulators
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
Dopamine receptor modulators
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Histamine receptor modulators
H1
Agonists
Antagonists
H2
Agonists
Antagonists
H3
Agonists
Antagonists
H4
Agonists
Antagonists
See also
Receptor/signaling modulators
Monoamine metabolism modulators
Monoamine reuptake inhibitors
Monoamine reuptake inhibitors
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
See also: Receptor/signaling modulatorsMonoamine releasing agentsAdrenergicsDopaminergicsSerotonergicsMonoamine metabolism modulatorsMonoamine neurotoxins
Muscarinic acetylcholine receptor modulators
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Nicotinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators
Serotonin receptor modulators
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
OCD pharmacotherapies
Antidepressants
Others
Portal: Categories: